| Abstract P160 – Table 1. Predictors of incident HIVAW among ART‐experienced people with HIV in OPERA® using two definitionsa,b of HIVAW. | ||||||
|---|---|---|---|---|---|---|
| Predictor at baselinec | Definition 1: N = 2306 with HIVAW | Definition 1: N = 36 860 without HIVAW | Definition 1: aORd (95% CI) | Definition 2: N = 2551 with HIVAW | Definition 2: N = 36 632 without HIVAW | Definition 2: aORd (95% CI) |
| Age, years | ||||||
| 18 to <40 | 947 (41) | 15 414 (42) | Reference | 913 (36) | 15 459 (42) | Reference |
| 40 to <55 | 790 (34) | 14 560 (40) | 0.76 (0.68 to 0.84) | 1021 (40) | 14 333 (39) | 1.04 (0.94 to 1.14) |
| ≥55 | 569 (25) | 6886 (19) | 0.92 (0.81 to 1.05) | 617 (24) | 6840 (19) | 1.12 (0.99 to 1.27) |
| Female sex | 443 (19) | 6823 (19) | 0.83 (0.73 to 0.93) | 583 (23) | 6683 (18) | 1.11 (1.00 to 1.23) |
| Black race | 1154 (50) | 16 926 (46) | 0.98 (0.89 to 1.08) | 1240 (49) | 16 846 (46) | 0.93 (0.85 to 1.02) |
| Hispanic ethnicity | 413 (18) | 8513 (23) | 0.78 (0.69 to 0.88) | 470 (18) | 8457 (23) | 0.79 (0.71 to 0.89) |
| Medicaid | 757 (33) | 10 039 (27) | 1.22 (1.11 to 1.34) | 873 (34) | 9924 (27) | 1.25 (1.15 to 1.37) |
| History of AIDS | 579 (25) | 8341 (23) | 0.96 (0.86 to 1.07) | 661 (26) | 8255 (23) | 0.96 (0.87 to 1.07) |
| VACS Mortality Indexe | ||||||
| 0 to <15 | 960 (42) | 19 713 (53) | Reference | 1126 (44) | 19 561 (53) | Reference |
| 15 to <30 | 705 (31) | 10 890 (30) | 1.36 (1.22 to 1.53) | 760 (30) | 10 838 (30) | 1.12 (1.00 to 1.25) |
| 30 to <45 | 343 (15) | 3768 (10) | 1.88 (1.61 to 2.20) | 335 (13) | 3776 (10) | 1.38 (1.18 to 1.60) |
| ≥45 | 298 (13) | 2489 (7) | 2.41 (2.00 to 2.90) | 330 (13) | 2457 (7) | 2.04 (1.71 to 2.43) |
| CD4 cell counte, cells/μL | ||||||
| ≥500 | 1316 (57) | 23 104 (63) | Reference | 1525 (60) | 22 907 (63) | Reference |
| 200 to <500 | 701 (30) | 10 824 (29) | 0.95 (0.86 to 1.06) | 735 (29) | 10 795 (29) | 0.93 (0.84 to 1.03) |
| 0 to <200 | 289 (13) | 2932 (8) | 1.07 (0.90 to 1.27) | 291 (11) | 2930 (8) | 1.02 (0.87 to 1.21) |
| Calendar year ART initiation | ||||||
| ≤2015 | 1373 (60) | 21 291 (58) | Reference | 1591 (62) | 21 069 (58) | Reference |
| 2016 to 2020 | 933 (40) | 15 569 (42) | 1.05 (0.94 to 1.18) | 960 (38) | 15 563 (42) | 1.01 (0.91 to 1.12) |
| Ever used INSTI | 1398 (61) | 22 859 (62) | 0.97 (0.88 to 1.06) | 1520 (60) | 22 748 (62) | 0.98 (0.90 to 1.07) |
| Ever used PI | 825 (36) | 11 445 (31) | 1.10 (1.00 to 1.21) | 956 (37) | 11 314 (31) | 1.13 (1.03 to 1.23) |
| Ever used TAF | 549 (24) | 10 118 (27) | 0.81 (0.72 to 0.92) | 550 (22) | 10 134 (28) | 0.78 (0.69 to 0.88) |
aOR, adjusted odds ratio; HIVAW, HIV‐associated wasting; INSTI, integrase strand transfer inhibitor; PI, protease inhibitor; PWHIV, people with HIV; TAF, tenofovir alafenamide; VACS, Veterans Aging Cohort Study.
aWasting diagnosis (ICD text or code), low BMI/underweight diagnosis (ICD text or code), or BMI measurement <20 kg/m2;
bwasting diagnosis (ICD text or code), low BMI/underweight diagnosis (ICD text or code), or two consecutive BMI measurements <18.5 kg/m2, or loss of ≥10% of baseline body weight within 12 months after baseline;
cbaseline = first date in the study period (2016 to 2020) where the PWHIV was HIV+, 18 years of age or older, and had an active OPERA® visit;
dadjusted for all variables in the table;
evalue closest to baseline: on or any time within 15 months prior to baseline if available; otherwise, up to 6 months after baseline (prior to censoring date).